Objective: To evaluate the long term efficacy and safety of long duration DAPT (L-DAPT) compared to short duration DAPT (S-DAPT) after drug-eluting stent (DES) implantation.
duration remains debatable. Several randomized control trials (RCTs) and meta-analysis including these trials have attempted to compare differences in outcomes between strategies of short (S) (3-6 months) and longer (L) (12-30 months) durations of DAPT and have reported conflicting results [3] [4] [5] [6] [7] [8] [9] [10] . In general, the events rates in these trials were small thereby affecting statistical power. Furthermore, the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation (OPTID-UAL) trial [10] which showed no reduction in ischemic events with L-APT (48 months) over standard (12 months) DAPT, after an extended median follow up of 33 months was prematurely terminated due to slow enrolment. In this background of the generally low rates of ischemic events at shorter follow ups, we conducted this updated meta-analysis to compare the efficacy and safety of strategies of S-DAPT versus L-DAPT strategy after DES implantation by restricting inclusion to randomized studies with follow-up durations of 24 months or longer.
| M E T H O D S

| Study design
We followed the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement for reporting systematic reviews and meta-analyses of RCTs for reporting results of our meta-analysis [11] . . DAPT was defined as aspirin plus a P2Y12 receptor inhibitor, after coronary DES implantation. S-DAPT and L-DAPT were defined as duration of DAPT after DES implantation of 12 months or less and longer than 12months, respectively. All relevant combinations of following keywords "aspirin," "P2Y12 receptor inhibitor," "clopidogrel," "Plavix," "prasugrel," "Effient," "ticagrelor," "Brilinta," "thienopyridine," "dual antiplatelet therapy," "DAPT," "drug eluting stent/s," "DES," "death," "mortality," "survival," "cardiac mortality," "stent thrombosis (ST)," stroke, myocardial infarction (MI), "randomized controlled trial," "random," "random allocation," "double-blind," and "single-blind" were included for database search. We hand searched references of identified studies. 
| Data sources and search strategy
| Data extraction
Two reviewers (AS, AG) independently screened the titles and abstracts for relevance. The manuscripts of selected titles/abstracts were reviewed for inclusion or exclusion using the above mentioned selection criteria.
Two reviewers (AS, AG) independently determined the articles to be included and excluded, and data from the relevant articles were extracted using pre-defined extraction forms. Any disagreements in data extraction were discussed until consensus was reached. Baseline patients characteristics and following data was extracted from selected studies at the end 
| Data analysis
The statistical analysis was performed according to the recommenda- Heterogeneity between studies was assessed using Cochrane's Q test and I 2 statistic, which denotes the percentage of total variation across studies that is a result of heterogeneity rather than chance. Heterogeneity was considered significant if the P value was less than 0.05. Publication bias was assessed by Begg's test and Egger's regression test.
| R E S U L T S 3.1 | Study outlines and characteristics
Our initial search identified 2,692 publications. After careful assessment of titles and abstracts, 11 studies were identified for review of full-text manuscripts. Five RCTs that met all inclusion criteria of this meta-analysis were finally included ( Figure 1 ) [3, 5, 6, 9, 10] . In these studies a total of 19,760 patients were randomized to S-DAPT (N 5 9,810) and L-DAPT (n 5 9,950). Mean follow up was 29.4 months.
Descriptors of included studies and baseline characteristics of patients enrolled in these studies are summarized in Tables 1 and 2 .
Mean age of enrolled patients ranged from 62 to 68 years. Male patients GUSTO, global utilization of streptokinase and tpa for occluded arteries; SVG, saphenous venous grafts; UPLMA, unprotected left main artery; DAPT, the dual antiplatelet therapy study; DES-LATE, the optimal duration of clopidogrel therapy with DES to reduce late coronary arterial thrombotic event; PRODIGY, prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study; SECURITY, second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy; OPTIDUAL, optimal duration of dual antiplatelet therapy after drug-eluting stent implantation; RESET, REal Safety and Efficacy of 3-month dual antiplatelet Therapy following endeavor zotarolimus-eluting stent implantation. Abbreviations: ACS, acute coronary syndrome; N, number of patients; DES, drug eluting stents; DM, diabetes mellitus; MI, myocardial infarction; DAPT, the dual antiplatelet therapy study; DES-LATE, the optimal duration of clopidogrel therapy With DES to reduce late coronary arterial thrombotic event; PRODIGY, prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study; SECURITY, second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy; OPTIDUAL, optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. 
FIG URE 2 Forest plot for stent thrombosis with S-DAPT and L-DAPT [Color figure can be viewed at wileyonlinelibrary.com]
| Clinical outcomes
Clinical outcomes with S-DAPT compared with L-DAPT are summarized in Table 3 The risk of ST, especially late (1 month to 1 year) and very late (>1 year) ST with newer-generation DES is low [14] . Such delayed ST events seem to result largely from impaired vessel healing and delayed endothelial coverage [15] , and a late hypersensitivity reaction to the drug-eluting polymer [16] . The most important independent predictor of ST is antiplatelet therapy discontinuation, especially when premature [17] . Extending duration of DAPT beyond 6-12 months might therefore reduce late and very late ST as well the small risk of non-stent related MI, and other atherosclerotic events that exists beyond 1 year in patients treated with coronary stents [18] . In the Dual Antiplatelet Therapy (DAPT) study [9] , DES treated patients (n 5 9,961) were randomized to an additional 18 months of DAPT or to aspirin monotherapy if they were free of ischemic or bleeding events on DAPT for 12 months previously. Extending DAPT resulted in significant reductions in rates of very late stent thrombosis and non-stent related thrombotic events paired with an increase in major bleeding. In the most recent OPTImal DUAL Antiplatelet Therapy (OPTIDUAL) trial [10] (n 5 1,385), outcomes in patients in whom clopidogrel was continued were compared with those in whom it was stopped 12 months after DES placement. There was a nominally lower rate of ischemic outcomes (combination of death, MI, or stroke) with prolonged DAPT but no difference in ST between the two groups. Similarly, in our metaanalysis of longer follow up studies there was no significant reduction in ST with L-DAPT compared with S-DAPT.
An unexpected finding in the DAPT study was a borderlinesignificant increase in all-cause mortality rate in patients treated with prolonged DAPT. Subsequent meta-analyses have found significant increase in risk of all-cause but not cardiovascular death with prolonged duration of DAPT in patients treated with predominantly newer DES, a finding largely driven by events in the DAPT trial [19] [20] [21] . A cause of death sub-analysis of the DAPT study [22] had previously found that the increase in all-cause mortality rates in the extended DAPT arm was driven entirely by an increase in non-cardiovascular deaths, and bleeding related deaths were few (0.3% vs. 0.2% continued DAPT vs. aspirin monotherapy, respectively). Rather, the difference was primarily attributed to a higher proportion of cancer at recruitment and cancer-related deaths among those randomized to the extended DAPT arm. Findings of our meta-analysis of no increase in either allcause or cardiovascular death are similar to those of a Food and Drug Administration drug safety communication [23] as well as of another analysis, both of which had concluded that long-term treatment with DAPT did not increase the risk of all-cause death or cardiovascular death [13] . The risk reduction in MI with L-DAPT in our study did not translate into a reduction in all-cause or cardiovascular mortality benefit. The thrombotic benefit of L-DAPT may have been counterbalanced by an increase in clinically significant major bleeding seen in our study.
Such bleeding increases mortality risk in patients treated with PCI, with suggestions from some studies that the hazard may indeed exceed that associated with an MI [24] . Therefore it is likely that no single DAPT duration is clearly superior in all patients with DES and decisions about duration of DAPT need to be individualized after incorporating an assessment of the risks of ischemia and bleeding. The "DAPT score"
derived from the DAPT study [25] provides a simple clinical tool to assess risk/benefit of extending DAPT in patients treated with a coronary stent. A score of 2 predicts a favorable benefit/risk ratio for continuing DAPT in patients treated for 1 year with DAPT without significant bleeding or ischemic events. Conversely, in those with a DAPT score <2, the risk/benefit ratio does not favor prolonged DAPT.
The current meta-analysis is the first to compare outcomes 
| C O NC LU S I O N S
In the present analysis of RCTs with longer follow up (2 years or longer), S-DAPT compared with L-DAPT, was associated with higher rate of MI and lower rate of major bleeding without any significant difference in the rates of all cause mortality, cardiac mortality, ST, TVR, and stroke.
